Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have received a consensus rating of “Moderate Buy” from the eight analysts that are covering the company, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $56.33.

Several research analysts have recently weighed in on the stock. StockNews.com upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Raymond James reiterated an “outperform” rating and set a $51.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Scotiabank lifted their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, December 9th. Royal Bank of Canada upped their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th.

Insider Activity at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,804 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. This represents a 12.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.93% of the stock is owned by company insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Erste Asset Management GmbH bought a new position in shares of Agios Pharmaceuticals in the 3rd quarter valued at about $97,199,000. Vestal Point Capital LP acquired a new stake in Agios Pharmaceuticals in the 3rd quarter valued at about $33,767,000. State Street Corp grew its holdings in Agios Pharmaceuticals by 10.2% during the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after purchasing an additional 216,484 shares during the period. Frazier Life Sciences Management L.P. increased its position in Agios Pharmaceuticals by 19.7% during the third quarter. Frazier Life Sciences Management L.P. now owns 1,044,154 shares of the biopharmaceutical company’s stock worth $46,392,000 after buying an additional 172,180 shares during the last quarter. Finally, Loomis Sayles & Co. L P raised its stake in Agios Pharmaceuticals by 36.4% in the third quarter. Loomis Sayles & Co. L P now owns 612,366 shares of the biopharmaceutical company’s stock valued at $27,208,000 after buying an additional 163,503 shares during the period.

Agios Pharmaceuticals Price Performance

NASDAQ AGIO opened at $34.38 on Thursday. The stock’s 50-day moving average is $38.84 and its 200-day moving average is $44.10. Agios Pharmaceuticals has a one year low of $23.41 and a one year high of $62.58. The firm has a market cap of $1.96 billion, a P/E ratio of 3.03 and a beta of 0.88.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.